← Back to Search

Virus Therapy

Vaccination for Tularemia

Phase 2
Waitlist Available
Led By Anthony Cardile, DO
Research Sponsored by U.S. Army Medical Research and Development Command
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This trial will test if a new vaccine for Francisella tularensis, the bacteria which causes tularemia, is safe and effective.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Microagglutination (MA) titer that shows a ≥ 4-fold rise in antibody titer after vaccination.
Number for adverse events.
Number of erythematous papule, vesicle, and/or eschar with or without underlying induration
Secondary outcome measures
Number of tularemia cases following exposure to F. tularensis in a successfully vaccinated individual

Side effects data

From 2012 Phase 3 trial • 6104 Patients • NCT01346592
27%
Injection site pain
25%
Pyrexia
14%
Decreased appetite
14%
Upper respiratory tract infection
14%
Diarrhea
10%
Injection site erythema
9%
Nasopharyngitis
9%
Irritability postvaccinal
9%
Headache
8%
Vomiting
8%
Injection site induration
7%
Myalgia
7%
Hypersomnia
7%
Injection site swelling
7%
Fatigue
6%
Crying
6%
Injection site hemorrhage
4%
Gastroenteritis
1%
Pneumonia
1%
Animal Bite
100%
80%
60%
40%
20%
0%
Study treatment Arm
ATIV (6 to <72 Months)
TIV (6 to <72 Months)
Comparator TIV (6 to <72 Months)

Trial Design

1Treatment groups
Experimental Treatment
Group I: VaccinationExperimental Treatment1 Intervention
Live Francisella Tularensis Vaccine

Find a Location

Who is running the clinical trial?

U.S. Army Medical Research and Development CommandLead Sponsor
286 Previous Clinical Trials
244,759 Total Patients Enrolled
2 Trials studying Tularemia
484 Patients Enrolled for Tularemia
Anthony Cardile, DOPrincipal InvestigatorUSAMRIID Medical Division
2 Previous Clinical Trials
1,000 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine
2009. "Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00787826.
~64 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top